生命科学资讯

The new rules of biopharma M&A: 4 trends driving dealmaking this year

Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says

New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill

Eikon sets $274M goal for upcoming stock market debut

Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M

Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss

Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report

CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'

FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling

'We have an expansive view:' Kardigan CEO knits sharper trials, digital health into cardio strategy

Boehringer channels midstage momentum into pivotal kidney disease trial

With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera

Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets

TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio

'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership

United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial

From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot

Lisata reclaims China rights to solid tumor candidate ahead of acquisition

After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy

Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance